Interim report into Gilenya safety released
Posted: Mon Apr 18, 2016 2:38 am
Once-daily Gilenya therapy is effective after four years of real-world clinical use among patients with relapsing remitting multiple sclerosis (RRMS), and has a safety profile that is “broadly consistent” with that identified in clinical trials, according to an interim analysis from the PANGAEA long-term safety, tolerability, and effectiveness non-interventional study, presented at the 68th annual American Academy of Neurology meeting...Read more - http://www.ms-uk.org/MSnews